Photo: Courtesy of Celgene ( Celgene Logo, https://www.celgene.com/media-library/celgene-logo/)

31 July 2015Americas

Celgene calls for Kyle Bass sanctions

Pharmaceutical company Celgene has requested that the US Patent and Trademark Office (USPTO) sanctions hedge fund manager Kyle Bass and his company the Coalition for Affordable Drugs, arguing that the inter partes review (IPR) petitions he has filed are “abusive” and a “tool to affect the stock prices of public companies”.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

USPTO rejects Celgene bid for Bass sanctions

28 September 2015 The US Patent and Trademark Office has rejected a request by biopharmaceutical company Celgene to sanction hedge fund manager Kyle Bass and his organisation the Coalition for Affordable Drugs.

Profit is at the heart of every IPR, says Kyle Bass

13 August 2015 Hedge fund manager Kyle Bass has fired a response to a motion filed by biotechnology company Celgene seeking to sanction him over “abusive” patent challenges, stating that profit motive is at the centre of every inter partes review filing.

More on this story

USPTO rejects Celgene bid for Bass sanctions

28 September 2015 The US Patent and Trademark Office has rejected a request by biopharmaceutical company Celgene to sanction hedge fund manager Kyle Bass and his organisation the Coalition for Affordable Drugs.

Profit is at the heart of every IPR, says Kyle Bass

13 August 2015 Hedge fund manager Kyle Bass has fired a response to a motion filed by biotechnology company Celgene seeking to sanction him over “abusive” patent challenges, stating that profit motive is at the centre of every inter partes review filing.

More on this story

USPTO rejects Celgene bid for Bass sanctions

28 September 2015 The US Patent and Trademark Office has rejected a request by biopharmaceutical company Celgene to sanction hedge fund manager Kyle Bass and his organisation the Coalition for Affordable Drugs.

Profit is at the heart of every IPR, says Kyle Bass

13 August 2015 Hedge fund manager Kyle Bass has fired a response to a motion filed by biotechnology company Celgene seeking to sanction him over “abusive” patent challenges, stating that profit motive is at the centre of every inter partes review filing.

More features

LSPN: In-house ‘chess game’ is the same, but the rules have changed

Life sciences leaders recognised at LSPN Awards USA 2025

UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body

LSPN: Counsel grapple with AI’s impact on training and critical thinking

'Nothing can stand in the way of our work': Ukraine resumes IP system

LSPN: Trump's policy storm causing chaos and confusion

Taylor Wessing expands in Europe with Paris team

LSPN: Using ‘the patentee’s friend’ in Section 112 claims